| Proteasome Inhibition Prevents Development of Experimental Dermal Fibrosis. | |
| | |
MedLine Citation:
|
PMID: 21882074 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Scleroderma is a chronic fibrotic disorder. Bortezomib, a proteasome inhibitor, is reported to attenuate experimentally induced renal and cardiac fibrosis. This study aimed to evaluate the preventive and therapeutic efficacies of bortezomib on a bleomycin (BLM)-induced scleroderma model. Dermal fibrosis was induced in Balb/c mice by subcutaneous BLM (100 μg/day) injections. Bortezomib (1.6 mg/kg twice/week) was applied intraperitoneally to BLM-injected mice during the first 3 weeks for preventive interventions and in the second 3 weeks for therapeutic interventions. IL-4 and TGF-β1 serum levels, dermal thicknesses, dermal inflammatory cell counts, and α-SMA-positive fibroblastic cell counts were determined, and type-I collagen, NF-κBp65, I-κBα, and JNK1 expressions were assessed. BLM applications increased serum IL-4 level, dermal inflammatory cell counts, α-SMA-positive cell counts, expression of type-I collagen, NF-κB, and JNK1, and dermal thickness in early stage of fibrosis, but serum IL-4 level and dermal inflammatory cell counts showed no increases in later stages. As a preventive intervention, bortezomib decreased dermal thickness, inflammatory cell infiltrations, fibroblastic activity, and expression of type-I collagen, NF-κB, and JNK1, but did not decrease fibroblastic activity and dermal thickness at later stages of fibrosis. Inflammatory status is prominent in the early stage of dermal fibrosis, but declines at later stages. In BLM-induced dermal fibrosis, bortezomib has a preventive anti-fibrotic and anti-inflammatory efficacy, but has no therapeutic anti-fibrotic efficacy in preexisting tissue fibrosis. These findings suggest that the effect of proteasome inhibition in early stages of dermal fibrosis may be related to its anti-inflammatory effects. |
| | |
Authors:
|
Suleyman Serdar Koca; Metin Ozgen; Ferda Dagli; Mehmet Tuzcu; Ibrahim Hanifi Ozercan; Kazim Sahin; Ahmet Isik |
Related Documents
:
|
10786654 - Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. 1391304 - Uterine epithelial cells synthesize granulocyte-macrophage colony-stimulating factor an... 1705744 - Lack of increase in granulocyte colony-stimulating factor in psoriatic skin. 20580464 - Heme oxygenase-1 expression in m-csf-polarized m2 macrophages contributes to lps-induce... 11139274 - Molecular mechanisms of cell death and phagocytosis in drosophila. 7972614 - Molecular biology of macrophage activation: a pathway whereby psychosocial factors can ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-1 |
Journal Detail:
|
Title: Inflammation Volume: - ISSN: 1573-2576 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600105 Medline TA: Inflammation Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, kocassk@yahoo.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Accelerating microfluidic immunoassays on filter membranes by applying vacuum.
Next Document: Bronchoalveolar Lavage Total Cell Count in Interstitial Lung Diseases-Does It Matter?